Annual report pursuant to Section 13 and 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)

v3.8.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended 12 Months Ended
Dec. 31, 2017
USD ($)
$ / shares
Sep. 30, 2017
USD ($)
$ / shares
Jun. 30, 2017
USD ($)
$ / shares
Mar. 31, 2017
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
$ / shares
Sep. 30, 2016
USD ($)
$ / shares
Jun. 30, 2016
USD ($)
$ / shares
Mar. 31, 2016
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
d
$ / shares
Dec. 31, 2016
USD ($)
$ / shares
Dec. 31, 2015
USD ($)
$ / shares
Oct. 06, 2017
USD ($)
May 03, 2016
Aug. 31, 2014
USD ($)
Jan. 31, 2010
right
Basis of Presentation [Line Items]                              
Maturity period of cash and cash equivalents, maximum                 3 months            
Write-downs related to obsolete inventory                 $ 0 $ 0          
Revenue $ 50,465,000 $ 33,375,000 $ 27,995,000 $ 29,267,000 $ 38,185,000 $ 21,619,000 $ 19,521,000 $ 29,648,000 141,102,000 108,973,000 $ 71,914,000        
Net income (loss) $ (7,007,000) $ 8,426,000 $ 6,058,000 $ 5,079,000 $ (3,125,000) $ 1,051,000 $ (6,170,000) $ 6,608,000 $ 12,556,000 $ (1,636,000) $ 229,824,000        
Earnings per share - diluted (USD per share) | $ / shares $ (0.33) $ 0.36 $ 0.26 $ 0.22 $ 0.15 $ 0.05 $ (0.30) $ 0.30 $ 0.53 [1] $ (0.08) [1] $ 10.83 [1]        
Restocking fee (as a percent)                 20.00%            
Share-based Compensation                              
Expected dividend rate (as a percent)                 0.00%            
Gain on disposition of product line                   $ 1,100,000          
Provision for taxes on gain from discontinued operations                 $ 0 408,000 $ 0        
Equity component of currently redeemable convertible notes (Note 6) $ 18,859,000       $ 29,563,000       18,859,000 29,563,000          
Excess tax benefit of share-based compensation                 4,700,000            
Retained earnings (accumulated deficit) $ (400,924,000)       (431,127,000)       $ (400,924,000) (431,127,000)          
Stock Options | 2002 Stock Incentive Plan                              
Share-based Compensation                              
Award expiration period                 10 years            
Stock Options | Vest 1/8 on the six month anniversary of the date of grant | 2002 Stock Incentive Plan                              
Share-based Compensation                              
Award vesting period                 6 months            
Award vesting right (as a percent)                 12.50%            
Stock Options | Vest 1/48 each month for forty-two months | 2002 Stock Incentive Plan                              
Share-based Compensation                              
Award vesting period                 42 months            
Award vesting right (as a percent)                 2.08%            
Minimum                              
Basis of Presentation [Line Items]                              
Property and equipment, useful life                 3 years            
Sales/revenues from partners reporting period                 30 days            
Maximum                              
Basis of Presentation [Line Items]                              
Property and equipment, useful life                 10 years            
Sales/revenues from partners reporting period                 60 days            
Crystal                              
Basis of Presentation [Line Items]                              
Value of share consideration                       $ 10,500,000.0      
Metabasis Therapeutics                              
Basis of Presentation [Line Items]                              
Number of contingent value rights | right                             4
Royalty Agreements                              
Basis of Presentation [Line Items]                              
Product royalty (as a percent)                         20.00%    
Aziyo | Royalty Agreements                              
Basis of Presentation [Line Items]                              
Proceeds from royalties received                 $ 10,000,000            
Product royalty (as a percent) 5.00%               5.00%            
Additional royalties receivable under sales-based milestones $ 10,000,000               $ 10,000,000            
Effective interest rate of forecasted cash flows (as a percent)                 26.00%            
CorMatrix | Royalty Agreements                              
Basis of Presentation [Line Items]                              
Product royalty (as a percent) 5.00%               5.00%            
Expiration period of royalty agreement                 10 years            
2019 Convertible Senior Notes                              
Share-based Compensation                              
Principal amount outstanding $ 245,000,000       $ 245,000,000       $ 245,000,000 245,000,000          
2019 Convertible Senior Notes | Senior Notes                              
Share-based Compensation                              
Principal amount outstanding                           $ 245,000,000.0  
Interest on debt instrument (as a percent)                           0.75%  
Working capital deficit 1,800,000               1,800,000            
Equity component of currently redeemable convertible notes (Note 6) 51,300,000               $ 51,300,000            
Threshold business days for repayment of principal                 3 days            
Number of consecutive trading days | d                 50            
Accounting Standards Update 2016-09                              
Share-based Compensation                              
Cumulative-effect adjustment from adoption of ASU 2016-09 18,103,000               $ 18,103,000            
Retained Earnings                              
Basis of Presentation [Line Items]                              
Net income (loss)                 12,556,000 (1,636,000) $ 229,824,000        
Retained Earnings | Accounting Standards Update 2016-09                              
Share-based Compensation                              
Cumulative-effect adjustment from adoption of ASU 2016-09 17,647,000     $ 17,900,000         17,647,000            
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09                              
Share-based Compensation                              
Retained earnings (accumulated deficit) $ 33,000,000               33,000,000            
Immaterial Error related to Contracts | Restatement Adjustment                              
Basis of Presentation [Line Items]                              
Revenue                 1,300,000 (1,300,000)          
Net income (loss)                 $ 800,000 $ (800,000)          
Earnings per share - diluted (USD per share) | $ / shares [1]                 $ 0.04 $ (0.04)          
[1] The sum of net income per share amounts may not equal the total due to rounding